- Home
- JTAI vs INTS Comparison
JTAI vs INTS Comparison
Compare JTAI & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JTAI
- INTS
- Stock Information
- Founded
- JTAI 2018
- INTS 2012
- Country
- JTAI United States
- INTS United States
- Employees
- JTAI N/A
- INTS N/A
- Industry
- JTAI Blank Checks
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- JTAI Finance
- INTS Health Care
- Exchange
- JTAI Nasdaq
- INTS Nasdaq
- Market Cap
- JTAI 9.9M
- INTS 9.4M
- IPO Year
- JTAI N/A
- INTS 2023
- Fundamental
- Price
- JTAI $3.74
- INTS $0.32
- Analyst Decision
- JTAI
- INTS Strong Buy
- Analyst Count
- JTAI 0
- INTS 3
- Target Price
- JTAI N/A
- INTS $8.50
- AVG Volume (30 Days)
- JTAI 332.2K
- INTS 2.7M
- Earning Date
- JTAI 08-13-2025
- INTS 08-07-2025
- Dividend Yield
- JTAI N/A
- INTS N/A
- EPS Growth
- JTAI N/A
- INTS N/A
- EPS
- JTAI N/A
- INTS N/A
- Revenue
- JTAI $13,648,668.00
- INTS N/A
- Revenue This Year
- JTAI $13.37
- INTS N/A
- Revenue Next Year
- JTAI $201.13
- INTS N/A
- P/E Ratio
- JTAI N/A
- INTS N/A
- Revenue Growth
- JTAI N/A
- INTS N/A
- 52 Week Low
- JTAI $2.30
- INTS $0.26
- 52 Week High
- JTAI $101.25
- INTS $5.10
- Technical
- Relative Strength Index (RSI)
- JTAI 42.97
- INTS 37.08
- Support Level
- JTAI $3.43
- INTS $0.28
- Resistance Level
- JTAI $3.95
- INTS $0.32
- Average True Range (ATR)
- JTAI 0.26
- INTS 0.06
- MACD
- JTAI -0.00
- INTS 0.01
- Stochastic Oscillator
- JTAI 17.39
- INTS 7.43
About JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as via Jet Token's leased and managed aircraft.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.